Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jun 3;17(1):401.
doi: 10.1186/s12885-017-3386-2.

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)

J V Reynolds  1 , S R Preston  2 , B O'Neill  3 , L Baeksgaard  4 , S M Griffin  5 , C Mariette  6 , S Cuffe  7 , M Cunningham  7 , T Crosby  8 , I Parker  9 , K Hofland  4 , G Hanna  9 , L B Svendsen  4 , C L Donohoe  7 , C Muldoon  7 , D O'Toole  7 , C Johnson  7 , N Ravi  7 , G Jones  8 , A K Corkhill  10 , M Illsley  2 , J Mellor  10 , K Lee  10 , M Dib  6 , V Marchesin  11 , M Cunnane  11 , K Scott  11 , P Lawner  11 , S Warren  7 , S O'Reilly  11 , G O'Dowd  11 , G Leonard  11 , B Hennessy  11 , R Mc Dermott  11
Affiliations
Clinical Trial

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)

J V Reynolds et al. BMC Cancer. .

Abstract

Background: Neoadjuvant therapy is increasingly the standard of care in the management of locally advanced adenocarcinoma of the oesophagus and junction (AEG). In randomised controlled trials (RCTs), the MAGIC regimen of pre- and postoperative chemotherapy, and the CROSS regimen of preoperative chemotherapy combined with radiation, were superior to surgery only in RCTs that included AEG but were not powered on this cohort. No completed RCT has directly compared neoadjuvant or perioperative chemotherapy and neoadjuvant chemoradiation. The Neo-AEGIS trial, uniquely powered on AEG, and including comprehensive modern staging, compares both these regimens.

Methods: This open label, multicentre, phase III RCT randomises patients (cT2-3, N0-3, M0) in a 1:1 fashion to receive CROSS protocol (Carboplatin and Paclitaxel with concurrent radiotherapy, 41.4Gy/23Fr, over 5 weeks). The power calculation is a 10% difference in favour of CROSS, powered at 80%, two-sided alpha level of 0.05, requiring 540 patients to be evaluable, 594 to be recruited if a 10% dropout is included (297 in each group). The primary endpoint is overall survival, with a minimum 3-year follow up. Secondary endpoints include: disease free survival, recurrence rates, clinical and pathological response rates, toxicities of induction regimens, post-operative pathology and tumour regression grade, operative in-hospital complications, and health-related quality of life. The trial also affords opportunities for establishing a bio-resource of pre-treatment and resected tumour, and translational research.

Discussion: This RCT directly compares two established treatment regimens, and addresses whether radiation therapy positively impacts on overall survival compared with a standard perioperative chemotherapy regimen Sponsor: Irish Clinical Research Group (ICORG).

Trial registration: NCT01726452 . Protocol 10-14. Date of registration 06/11/2012.

Keywords: Adenocarcinoma; Neoadjuvant chemoradiation therapy; Neoadjuvant chemotherapy; Oesophageal; Oesophagogastric junction.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schedule of enrolment, interventions, and assessments
See this image and copyright information in PMC

References

    1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–2252. doi: 10.1056/NEJMra035010. - DOI - PubMed
    1. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499. doi: 10.1056/NEJMra1314530. - DOI - PubMed
    1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–412. doi: 10.1016/S0140-6736(12)60643-6. - DOI - PubMed
    1. Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232(3):353–361. doi: 10.1097/00000658-200009000-00007. - DOI - PMC - PubMed
    1. Van Vliet E, Heijenbrok-Kal M, Hunink M, Kuipers E, Siersema P. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98(3):547–557. doi: 10.1038/sj.bjc.6604200. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data